Medlab Clinical Future Growth
Future criteria checks 2/6
Medlab Clinical's earnings are forecast to decline at 21.4% per annum while its annual revenue is expected to grow at 27.4% per year. EPS is expected to grow by 9.3% per annum.
Key information
-21.4%
Earnings growth rate
9.3%
EPS growth rate
| Biotechs earnings growth | 15.0% |
| Revenue growth rate | 27.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 9 | -19 | N/A | -19 | 1 |
| 6/30/2023 | 6 | -14 | N/A | -17 | 2 |
| 6/30/2022 | 6 | -11 | N/A | -8 | 2 |
| 12/31/2021 | 4 | -12 | -11 | -11 | N/A |
| 9/30/2021 | 4 | -12 | -11 | -11 | N/A |
| 6/30/2021 | 4 | -12 | -10 | -10 | N/A |
| 3/31/2021 | 2 | -11 | -9 | -9 | N/A |
| 12/31/2020 | 1 | -11 | -8 | -8 | N/A |
| 9/30/2020 | 2 | -12 | -10 | -9 | N/A |
| 6/30/2020 | 3 | -13 | -11 | -10 | N/A |
| 3/31/2020 | 4 | -12 | -11 | -11 | N/A |
| 12/31/2019 | 4 | -12 | -12 | -12 | N/A |
| 9/30/2019 | 5 | -10 | -11 | -11 | N/A |
| 6/30/2019 | 5 | -8 | -11 | -10 | N/A |
| 3/31/2019 | 5 | -7 | -9 | -9 | N/A |
| 12/31/2018 | 5 | -6 | -7 | -7 | N/A |
| 9/30/2018 | 4 | -5 | -6 | -6 | N/A |
| 6/30/2018 | 4 | -5 | -5 | -5 | N/A |
| 3/31/2018 | 4 | -4 | -5 | -5 | N/A |
| 12/31/2017 | 5 | -4 | -5 | -5 | N/A |
| 9/30/2017 | 5 | -4 | -4 | -4 | N/A |
| 6/30/2017 | 4 | -4 | -4 | -4 | N/A |
| 3/31/2017 | 4 | -4 | -4 | -4 | N/A |
| 12/31/2016 | 4 | -4 | -4 | -4 | N/A |
| 9/30/2016 | 3 | -4 | -4 | -4 | N/A |
| 6/30/2016 | 3 | -3 | -4 | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDCDA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MDCDA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MDCDA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MDCDA's revenue (27.4% per year) is forecast to grow faster than the Australian market (5.2% per year).
High Growth Revenue: MDCDA's revenue (27.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MDCDA's Return on Equity is forecast to be high in 3 years time